Table 1 Patient demographics (n = 86).
From: Efficacy of galcanezumab in migraine central sensitization
Age and sex | ||
|---|---|---|
Age at study [years (mean ± SD)] | 42.8 ± 11.1 | |
Age at onset of migraine [years (mean ± SD)] *n = 79 | 15.5 ± 7.3 | |
Females [cases (%)] | 73 (84.9%) | |
Diagnosis | ||
EM [cases (%)] | 26 (30.2%) | |
CM with MOH [cases (%)] | 40 (46.5%) | |
CM without MOH [cases (%)] | 20 (23.3%) | |
Characteristics of headache | ||
Attack duration [hours, median (IQR)] | 6 (4.8–13.3) | |
Headache laterality [cases (%)] | Strictly unilateral | 6 (7.0%) |
Unilateral side variable | 15 (17.4%) | |
Bilateral or unilateral | 50 (58.1%) | |
Always bilateral | 15 (17.4%) | |
Monthly days with moderate headaches (mean ± SD) | 7.7 ± 6.1 | |
Monthly days with severe headaches (mean ± SD) | 3.6 ± 4.8 | |
Pulsating quality [cases (%)] | 41 (47.7%) | |
Aggravation by routine physical activity [cases (%)] | 66 (76.7%) | |
Nausea and/or vomiting [cases (%)] | 55 (64.0%) | |
Photophobia [cases (%)] | 71 (82.6%) | |
Phonophobia [cases (%)] | 60 (69.8%) | |
Osmophobia [cases (%)] | 55 (64.0%) | |
Treatments | ||
Days with acute medication use/month (mean ± SD) | 10.4 ± 6.7 | |
Concomitant preventive treatment [cases (%)] | 59 (68.6%) | |
Past medical history | ||
Restless leg syndrome [cases (%)] | 2 (2.3%) | |
Temporomandibular joint disorder [cases (%)] | 13 (15.1%) | |
Irritable bowel syndrome [cases (%)] | 11 (12.8%) | |
Multiple chemical sensitivities [cases (%)] | 2 (2.3%) | |
Neck injury (including whiplash) [cases (%)] | 12 (14.0%) | |
Anxiety or panic attacks [cases (%)] | 14 (16.3%) | |
Depression [cases (%)] | 18 (20.9%) | |
